Home / News / Events / Events detail
2022 New Target, New Technology Conference
On June 23, 2022, the New Target, New Technology Conference was held in Chengdu with some participants joining virtually. A number of experts in the field of new drug research and development joined to share their interpretations and thoughts on the current situation. Dr. Xueheng Cheng, CTO of Viva Biotech, was invited to attend the conference and shared the recent progress of FBDD and other new small molecule drug discovery technologies.
Dr. Cheng emphasized the advantages of FDBB over HTS: "Compared with HTS, the molecular weight of fragment compounds is smaller, the hit compounds have more potential, and there is more room for structural optimization in the future. Secondly, the fragment compounds have a higher degree of fit with the protein binding site and are expected to become a leading high-affinity binding compound."
In addition, Dr. Cheng demonstrated the important role of Viva Biotech in the discovery of new drugs. To provide the world's leading early-stage structure-based drug development services, Viva has efficient target preparation, possesses a comprehensive compound library, and covers the whole process of medicinal chemistry and computational chemistry.
LSX World Congress USA: Biotech Leaders
LSX World Congress USA: Biotech Leaders was held on June 21st-22nd. The conference focused on popular areas such as investment, cooperation, and strategic layout. Sally Wang, Venture Partner of Viva BioInnovator, was invited to lead a panel discussion which provided insights on early science generation, team building, current market adaptations, and strategic planning and methodology. Sally also provided feedback on a series of biotech pitches as part of an Expert Investor Panel, which included our portfolio company, AceLink.
Antibody Drug Differentiation Innovation and Cooperation Ecosystem Sharing Session
On June 18, Pineclub and Viva BioInnovator(VBI) jointly hosted the " Antibody Drug Differentiation Innovation and Cooperation Ecosystem Sharing Session". A number of representative companies of innovative antibody drug from the industry ecosystem gathered online to discuss the differentiation of antibody R&D, Innovation and cooperation layout. As an invited guest, Dr. Han Dai, Chief Innovation Officer of Viva Biotech and head of Viva BioInnovator, introduced the development of EFS business and the investment/incubation layout of Via Biotech in the field of innovative antibodies. Viva BioInnovator (VBI) will further focus on building professional post-investment management system, continuously improve service capabilities from CRO/CDMO, expert support, capital, industrial relationship network and operations, as well as continue to build and optimize biopharmaceutical innovation ecosystem.
Drug Times’ Live Broadcast Room | New Drug APIs’ R&D, Production & Declaration
On May 27th, Dr. Jianguo Ma, Senior Vice President of Viva Biotech and CEO of Langhua Pharmaceuticals, was invited to attend Drug Times' live broadcasting room. Because of Langhua's successful experience, he shared his expertise and insights on "New Drug API R&D, Production, and Declaration. "
Regarding the topic of "Key Points of IND Application for APIs," Dr. Ma pointed out: "At present, innovative drugs are ushering in a big explosion. Many companies intensively launch this kind of product. Quality, production cost control, and speed are the keys to competition. In the entire project process of serving customers, Langhua pays great attention to product quality control and management, delivery speed, and production cost control. From early development to commercial production, we always pay attention to these three factors as the focus of project execution management. Through various technical methods, we deliver efficient, high-quality, and low-cost products to our customers.”
How to help R&D projects advance to IND filing and subsequent NDA filing as quickly as possible? Dr. Ma said Langhua has a first-class R&D team, sufficient capacity supply, advanced API and preparation technology platform, reliable GMP and EHS management system, and a perfect IP protection system. This allows Langhua to offer our worldwide partners a one-Stop CDMO solution in a new drug's entire life cycle for small molecule Active Pharmaceutical Ingredients (APIs) and Finished Dosage Form, from pre-clinical to commercial supply.
Copyright © Viva Biotech All Rights Reserved. 沪ICP备19036061号
- About Us
-
CRO Services
BackCRO ServicesDiscovery Biology Services
- CDMO Services
- EFS Business
- News
- Careers
- Investor Relations
- Contact Us